Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599521 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,067
- Enrollment target
NCT00599521 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 1,067 participants.
The verdict
NCT00599521, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,067 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.
Interventions
- DRUG Adapalene lotion 0.1%
- DRUG Adapalene Lotion Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,067 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00599521
The ClinicalTrials.gov registry entry for NCT00599521 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,067 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adapalene lotion 0.1% is the first listed.
NCT00599521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00599521 about?
NCT00599521 is a clinical study titled "Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%". The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.
What is the current status of trial NCT00599521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,067 participants. The study started on 2007-11. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00599521?
The interventions under investigation include: Adapalene lotion 0.1% (DRUG), Adapalene Lotion Vehicle (DRUG).
Who is sponsoring clinical trial NCT00599521?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.